Actin Peptide IgG

If your liver enzymes come back high and no one can explain why, this antibody helps fill in the blank. A positive result points toward autoimmune hepatitis, a disease where your immune system attacks liver cells.

The name causes a lot of confusion. This is an antibody measured from serum after a blood draw. It is not a peptide you swallow or inject to build muscle, and it has nothing to do with steroids or workout supplements.

What This Antibody Actually Is

Actin Peptide IgG, also called anti-F-actin IgG, is an antibody aimed at actin. Actin is one of the most common proteins inside your cells. It forms tiny filaments that give cells their shape and let them contract.

In autoimmune hepatitis, your immune system can start making IgG antibodies against F-actin. IgG is the long-lasting class of antibody. The lab measures these antibodies in serum. Serum is the liquid part of blood after clotting. Anti-F-actin belongs to the larger family of smooth muscle antibodies, because smooth muscle contains a lot of actin.

Autoimmune Hepatitis

Anti-F-actin IgG is one of the stronger blood markers for type 1 autoimmune hepatitis, the most common form. The adult data are strongest for serum ELISA testing. ELISA is a common color-change lab method. In a multicenter adult study, the test separated people with autoimmune hepatitis from controls with an accuracy score around 0.88 on a scale where 1.0 is perfect and 0.5 is a coin flip.

At the looser setting in that study, the ELISA caught about 81 of every 100 people with the disease and correctly cleared about 82 of 100 without it. At the stricter setting, it caught fewer cases, about 66 of 100, but correctly cleared more people without disease, about 93 of 100. These exact trade-offs are specific to that study rather than fixed test characteristics. In children, ELISA-based anti-F-actin also performed well in autoimmune hepatitis and autoimmune sclerosing cholangitis.

Among people with autoimmune hepatitis who are smooth muscle antibody positive, anti-actin antibodies show up in roughly 86% to 100% of cases, and the exact number changes with method and lab cutoff. High-level results are rare in healthy blood donors. That is why the marker belongs in the workup. It is still a confirming piece, not a solo diagnosis, because autoimmune hepatitis is diagnosed from a pattern: enzymes, total IgG, autoantibodies, and often biopsy.

In one ANA-positive adult cohort comparing autoimmune hepatitis with drug-induced liver injury, F-actin ELISA performed close to smooth muscle antibody and total IgG, and better than several other autoantibodies. The study did not show that anti-F-actin alone can separate autoimmune hepatitis from every drug or supplement reaction.

What Your Level Says Over Time

The number is more useful as part of a pattern than as a one-off reading. In people already treated for autoimmune hepatitis, studies using microscope-based anti-actin titers found that titers staying high after treatment tracked with disease that was still active. About 80% still had inflammation on blood tests, and biopsy showed inflammation in every assessed case. The strongest monitoring data come from these microscope-based titers rather than ELISA.

A titer is a dilution test. If the antibody is still seen after more dilution, the titer is higher.

A related antibody against alpha-actinin adds to this picture. Alpha-actinin helps anchor actin filaments. In type 1 autoimmune hepatitis, people positive for both anti-F-actin and anti-alpha-actinin were much more likely to have active, sudden-onset disease than people without both. This is related research, not the same analyte this test measures.

When It Turns Up Without Liver Disease

A positive result does not always mean autoimmune hepatitis. Low levels appear in other liver conditions, including primary biliary cholangitis and viral hepatitis. In one acute viral hepatitis antibody-positive group, about a quarter were F-actin IgG positive, usually at low levels. Healthy blood donors rarely test positive, and when they do it tends to be low.

Anti-actin antibodies have also been studied in celiac disease. Those studies mostly measured IgA, not the IgG this test detects. Findings from celiac IgA studies do not transfer directly here.

Why the Method Matters

This test can be run in different ways, and they do not fully agree. The serum ELISA used for many F-actin IgG tests is not interchangeable with microscope-based smooth muscle antibody testing. ELISA can reduce reader-to-reader variation, but studies show the best cutoff has to be validated by each lab and false negatives can happen when suspicion is high.

Context changes the meaning. A positive result is not a verdict on its own. In someone with a healthy liver and no reason to suspect autoimmune disease, a positive is more likely a false alarm or a harmless low-level reading than early disease. The same number means very different things depending on the clinical picture around it.

Why One Reading Is Not Enough

A single result is a snapshot. Antibody levels can move with disease activity and with treatment, and the method varies between labs, so one number in isolation can mislead in either direction. The value comes from watching whether it lines up with ALT, AST, total IgG, symptoms, and sometimes biopsy.

If you are checking this because of unexplained liver inflammation, pair the result with liver enzymes and total IgG. If you are diagnosed and being treated, repeat results only matter when they move with the rest of the liver picture. A falling antibody by the same method can be reassuring; a high result that stays high while enzymes or IgG remain abnormal is a reason to look harder.

What to Do With an Unexpected Result

A positive result is a starting point, not an endpoint. The next move is to look at the whole liver-autoimmune picture rather than react to one antibody.

• Liver enzymes and IgG: check ALT, AST, GGT, and total IgG. Autoimmune hepatitis usually comes with raised enzymes and high total IgG. Normal values alongside a positive antibody argue against active disease.
• Companion autoantibodies: check ANA and smooth muscle antibody by microscope to round out the pattern. Mitochondrial antibody (AMA-M2) helps separate autoimmune hepatitis from primary biliary cholangitis.
• Specialist and biopsy: a positive antibody plus high enzymes and high IgG is a reason to involve a hepatologist. Diagnosis usually still needs liver biopsy.
• Watchful waiting: a positive antibody with normal enzymes and no symptoms usually means repeat liver labs and context, not treatment.

When Results Can Be Misleading

• Other liver conditions: low-level positives show up in viral hepatitis and primary biliary cholangitis, where they do not mean autoimmune hepatitis.
• Method and lab differences: ELISA and microscope-based tests can disagree, and cutoffs are not standardized, so results from different labs are not interchangeable.
• Low pre-test probability: in people with no signs of liver disease, most positive results are false positives, because a rare condition tested in healthy people produces many false alarms for each true case.
• Current or recent immunosuppression: treatment can lower antibody levels, so a quieter result has to be read alongside ALT, AST, total IgG, and the treatment history.